Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of GSK3358699 in Healthy Males
NCT03426995Phase 1Terminated
- Sponsor
- GSK
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3358699 in rheumatoid arthritis (RA) (8 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Worst Case Chemistry Results and 4 more. Started Mar 2018; status: terminated.
02
Drugs
GSK3358699
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03426995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426995.